US 11,693,017 B2
Small molecule biosensors
Daniel J. Mandell, Brookline, MA (US); Justin Feng, Cambridge, MA (US); Xavier Rios Villanueva, Boston, MA (US); and Rajagopal Chari, Brighton, MA (US)
Assigned to President and Fellows of Harvard College, Cambridge, MA (US)
Appl. No. 15/760,352
Filed by President and Fellows of Harvard College, Cambridge, MA (US)
PCT Filed Jan. 12, 2016, PCT No. PCT/US2016/013005
§ 371(c)(1), (2) Date Mar. 15, 2018,
PCT Pub. No. WO2017/048316, PCT Pub. Date Mar. 23, 2017.
Claims priority of provisional application 62/220,628, filed on Sep. 18, 2015.
Prior Publication US 2018/0259541 A1, Sep. 13, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/74 (2006.01); C07K 14/00 (2006.01); C12N 15/62 (2006.01); C12N 15/63 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/90 (2006.01)
CPC G01N 33/743 (2013.01) [C07K 14/00 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/62 (2013.01); C12N 15/63 (2013.01); C12N 15/902 (2013.01); C07K 2319/00 (2013.01); C12N 2310/20 (2017.05); C12N 2320/50 (2013.01); C12N 2800/22 (2013.01); C12N 2800/80 (2013.01)] 9 Claims
OG exemplary drawing
 
1. A conditionally stable biosensor comprising a homodimeric ligand binding domain (LBD) having conditionally-destabilizing mutations that is fused to a trans-activation domain (TAD) and a DNA binding domain (DBD), wherein the conditionally stable biosensor is stabilized when the ligand binding domain is bound to a cognate steroid, and wherein the DNA binding domain (DBD) binds to DNA and the trans-activation domain (TAD) activates transcription of a target gene.